Literature DB >> 15313698

Intralesional bleomycin injections for the palliation of epistaxis in hereditary hemorrhagic telangiectasia.

Ian C Duncan1, Leon Van Der Nest.   

Abstract

Epistaxis is a common complication in patients with hereditary hemorrhagic telangiectasia. Its treatment is generally aimed at controlling the frequency and severity of nasal hemorrhage and involves surgery, transcatheter embolization, topical treatment, or a combination. Despite this multitude of treatment methods, the long-term prognosis for many patients remains poor. We describe a patient in whom direct intralesional injections of bleomycin successfully palliated severe recurrent epistaxis for almost 2 years without the need for adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313698      PMCID: PMC7976547     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  15 in total

1.  Hereditary hemorrhagic telangiectasis treated by the harmonic scalpel.

Authors:  Toshio Ishibashi; Shunsuke Takamatsu
Journal:  Head Neck       Date:  2003-04       Impact factor: 3.147

2.  Efficacy of bleomycin treatment for symptomatic hemangiomas in children.

Authors:  C M Kullendorff
Journal:  Pediatr Surg Int       Date:  1997-09       Impact factor: 1.827

3.  Inhibition of angiogenesis by bleomycin and its copper complex.

Authors:  T Oikawa; K Hirotani; H Ogasawara; T Katayama; H Ashino-Fuse; M Shimamura; T Iwaguchi; O Nakamura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1990-06       Impact factor: 1.645

Review 4.  A radical approach to cancer.

Authors:  Undurti Das
Journal:  Med Sci Monit       Date:  2002-04

5.  [An experimental study on effects of pingyangmycin on vessels].

Authors:  Q Gao; C Wang; Y Wen; L Li; J Zhang; Z He; Z Yang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2001-06

6.  [Treatment of hemangioma in oral and maxillofacial region with pingyangmycin injection].

Authors:  C Wang; Q Gao; F Fu; Y Wen; X Dai; H Gong; X Lu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2000-10

7.  Bleomycin.

Authors:  J M Bennett; S D Reich
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

Review 8.  Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations.

Authors:  T Muir; M Kirsten; P Fourie; N Dippenaar; G O Ionescu
Journal:  Pediatr Surg Int       Date:  2004-01-22       Impact factor: 1.827

Review 9.  Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century.

Authors:  M E Begbie; G M F Wallace; C L Shovlin
Journal:  Postgrad Med J       Date:  2003-01       Impact factor: 2.401

10.  Sclerotherapy for lymphangioma in children.

Authors:  I Sanlialp; I Karnak; F C Tanyel; M E Senocak; N Büyükpamukçu
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2003-07       Impact factor: 1.675

View more
  4 in total

1.  Vascular sclerosing effects of bleomycin on cutaneous veins: a pharmacopathologic study on experimental animals.

Authors:  Khalid M AlGhamdi; Ashok Kumar; Abdelkader E Ashour; Ammar C Al-Rikabi; Abdullah Hasan AlOmrani; Shaik Shaffi Ahamed
Journal:  An Bras Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.896

2.  Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.

Authors:  Holly Boyer; Patricia Fernandes; Chap Le; Bevan Yueh
Journal:  Int Forum Allergy Rhinol       Date:  2015-02-02       Impact factor: 3.858

3.  Endovascular treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.

Authors:  K F Layton; D F Kallmes; L A Gray; H J Cloft
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

4.  Symptomatic abdominal simple cysts: is percutaneous sclerotherapy with hypertonic saline and bleomycin a treatment option?

Authors:  V D Souftas; M Kosmidou; M Karanikas; D Souftas; G Menexes; P Prassopoulos
Journal:  Gastroenterol Res Pract       Date:  2015-03-23       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.